Beriglobin 2ml. 5ml Injection

Indication

Replacement therapy in patients with primary immunodeficiency syndromes and for the treatment of certain autoimmune diseases.

Dosage (summary)

The dosage varies based on the indication and patient weight; typically, 0.4 to 1 g/kg body weight administered intravenously or subcutaneously, depending on the condition being treated.

Onset of Action / Duration

Onset of action is usually within a few hours to days, depending on the route of administration and the condition being treated.

Special Populations

• Elderly patients
• Patients with renal impairment
• Patients with hepatic impairment

Pregnancy & Breastfeeding

Beriglobin can be used during pregnancy and lactation if the benefits outweigh the risks, as human immunoglobulin is generally considered safe.

Key Drug Interactions

• Live attenuated vaccines may have reduced efficacy when administered concurrently with immunoglobulin therapy.
• Caution is advised when administering with other immunosuppressive therapies.

Contraindications

• Hypersensitivity to human immunoglobulin or any component of the formulation.
• Severe hyperprolinemia (in patients with specific genetic disorders).

Common side effects

• Headache
• Fever
• Chills
• Nausea
• Fatigue
• Injection site reactions

Counselling Points

• Inform patients about the potential for allergic reactions and advise them to report any unusual symptoms.
• Advise patients to stay hydrated during and after infusion.
• Educate patients on the importance of adhering to the prescribed dosage and schedule.